MAM
NBA strengthens China focus with Panini Group deal
MUMBAI: The National Basketball Association (NBA) and sports and entertainment collectibles company the Panini Group have announced an extension of their partnership through a new multi-year agreement.
Under the terms of the new agreement, Panini will continue to be the exclusive trading card and sticker partner for the NBA globally, expanding its current development and distribution of trading cards and products worldwide, with a particular focus on China. The relationship will be managed by the Panini Group‘s U.S. subsidiary, Panini America.
This renewal reinforces Panini‘ position as the only company in the world to manufacture official trading cards and stickers for the NBA, NFL, NFLPA, NHL, NHLPA, MLBPA, and FIFA World Cup. Panini‘s array of NBA products, which include “National Treasures” and “Prestige,” is designed to attract new and existing collectors, and to establish a high-end marketplace for NBA trading cards and related products domestically and internationally.
NBA executive VP global merchandising group Sal LaRocca said, “Our companies share a collective interest in promoting our brands worldwide. Panini has continually demonstrated the ability and commitment to creating products that appeal to our fans on a global basis.”
Panini America CEO Mark Warsop said, “The popularity of the NBA game globally is unmatched and, with new NBA superstars emerging, it‘s an exciting time to collect NBA trading cards, which are not only fun but highly sought after in the secondary trading card market. In the last three years, there has not been a more valuable modern-day trading card than our National Treasures NBA product that included a 1-of-1 Blake Griffin NBA Logoman Rookie card that sold on the secondary market for $38,000. This new long-term agreement with the NBA serves as the foundation to our future growth and our long-term commitment to the trading card category.”
The Panini Group has relationships with players, including five-time NBA champion Kobe Bryant of the Los Angeles Lakers, Kevin Durant of the Oklahoma City Thunder, and Blake Griffin of the Los Angeles Clippers. In May Panini Authentic, Panini‘s memorabilia division, signed the Dallas Mavericks as its first exclusive game-worn team partner. Panini also has relationships with USA Basketball, USA Baseball, the U.S. Soccer Women‘s National Team, the Pro Football Hall of Fame, Naismith Memorial Basketball Hall of Fame, Disney, Hello Kitty, Justin Bieber, One Direction and Michael Jackson and more than 600 global licenses with other sports and entertainment properties.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
